Veeda appoints Venu Madhav as COO
Veeda Clinical Research has appointed Venu Madhav as the COO of its
unit in India. He has 19 years of experience in clinical research. He
has been associated with reputed companies such as Ranbaxy and Sun
Pharma especially during the growth period of these organizations.
Madhav carries rich experience in planning bioequivalence studies from
pilot to pivotal stage for generic formulations. He has designed
clinical, bioanalytical, pharmacokinetic and statistical aspects of
bioavailability and bioequivalence studies.
Dr David U'Prichard joins Ocimum
Ocimum Biosolutions has appointed Dr David U'Prichard, president at
Druid Consulting, to the board of directors. He holds several board
positions in life sciences companies globally that include Life
Technologies, Oxagen and Cyclacel. He is also a venture partner at Red
Abbey Venture Partners.
Anu Acharya, CEO, Ocimum Biosolutions, said, “We are delighted to have
Dr David U'Prichard on our board of directors. David's wealth of
expertise in the biotech and pharma, venture capital and a strong
academic background makes him a great source of wisdom for the road
ahead for Ocimum.”
Bishwajeet Roy joins Finar
Chemicals as COO
Bishwajeet Roy, a veteran chemical industry professional and former
executive director of ThermoFisher Scientific has joined Finar
Chemicals, an Ahmedabad-based manufacturer of laboratory and fine
chemicals as the chief operating officer. He has over 31 years of
industry experience and has held significant portfolios in his career.
Actis Biologics promotes Dr Gopal
Dasika as CSO
Actis Biologics has promoted Dr Gopal Dasika to the position of chief
scientific officer. He joined the company in 2009 as senior vice
president of R&D, in place of Dr Ramani Aiyer, who had shifted to
the US and has been associated with the US-arm of the company.
Prior to joining Actis, Dr Dasika worked as the head, Biology Research
at Reliance Life Sciences. He has worked on the development of
biosimilars, fusion proteins, monoclonal antibodies, and platform
technology for protein expression. He is an adjunct faculty in
biotechnology, University of Mumbai.
He was a great visionary leader
Subhash Bagaria will be remembered for his three decades of visionary
leadership and his pioneering efforts in bringing and establishing
world-class technologies, capabilities and infrastructure to India in
diverse areas such as life sciences services for the research,
development and production of biopharmaceutical drugs, validation and
process development facilities, and contract manufacturing.
In 1986, he formed Millipore India, a joint venture with Millipore
Corporation, US. Over the last two decades Bagaria had grown Millipore
India into an undisputed market leader providing products and services
that improve productivity in biopharmaceutical manufacturing and in
life sciences research.
As the chairman and MD of Kemwell, he transformed the company into a
leading provider of formulations contract manufacturing and development
services. Today, Kemwell has four manufacturing facilities in Bangalore
and one facility in Uppsala, Sweden. Among Bagaria's philanthropic
efforts were Charity Foundations that provided scholarships to
deserving students and medical help to needy patients. The Foundation
has set up the Paediatric Intensive Care Unit in Narayana Hrudayalaya,
Bangalore, and also a Tibetan Medical Center in Bangalore.
"After working with him for over 26 years, I respect him both as a
mentor and as an insightful business leader. Usually, Subhashji was far
ahead of the times in anticipating the needs of the Indian
biopharmaceutical industry. The several start-ups that he conceived,
nurtured and grew over the years were successful in getting some of the
best technologies in the area, accessible to the Indian
biopharmaceutical industry. He backed his beliefs with all the
investments required for building truly world-class facilities. As an
astute business leader, he had a rare ability to be on top of market
trends and market dynamics and insisted on proper market preparedness
in terms of pro-activeness. The success of his enterprises and their
pioneering contributions are evident to those who worked closely with
him because he was usually media shy and self effacing"
Kant, president, Millipore India.